Navigation Links
Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
Date:4/28/2008

SOUTH SAN FRANCISCO, Calif., April 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) will release its first quarter 2008 financial results on Tuesday, May 6, 2008, after the markets close. The announcement will be followed by a live webcast at 2:00 p.m. PT/5:00 p.m. ET, in which Exelixis management will discuss the first quarter financial results and give a general update on the company's financial position and business, including its development pipeline and corporate strategy. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 8:59 p.m. PT/11:59 p.m. ET on June 6, 2008. Access numbers for this replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is 37936947.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
2. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
3. Option to Develop Exelixis Compound Exercised By Genentech
4. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
5. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
6. Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
7. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
8. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
9. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
10. Exelixis Announces Senior Management Promotions
11. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, ... duties on May 15, 2017. , Dr. Terzella completed his residency in Physical ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... recognized outstanding manufactures in 10 categories with over 30 nominees and well as ... Manufacturing presented the new award and the event was hosted by CompanyWeek and ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):